These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 33713744)
1. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial. Li R; Liu Y; Yin R; Yin L; Li K; Sun C; Zhou Z; Li P; Tong R; Xue J; Lu Y Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1432-1441. PubMed ID: 33713744 [TBL] [Abstract][Full Text] [Related]
2. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy. Ao M; Li P; Sun D; Li X; Xu S; Hao Y J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548 [TBL] [Abstract][Full Text] [Related]
3. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women. Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676 [TBL] [Abstract][Full Text] [Related]
4. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603 [TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
6. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
7. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older. Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592 [TBL] [Abstract][Full Text] [Related]
8. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290 [TBL] [Abstract][Full Text] [Related]
9. PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer. Wang C; Liu L; Li X; Lei J; Li Y; Shen Z; Shi H; Cheng Y Future Oncol; 2024; 20(20):1415-1426. PubMed ID: 38861299 [TBL] [Abstract][Full Text] [Related]
10. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K; Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750 [TBL] [Abstract][Full Text] [Related]
12. Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer. Berenguer Frances MA; Linares-Galiana I; Cañas Cortés R; Marín I Borrás S; Gutiérrez Miguélez C; Najjari D; Slocker A; Bellobí C; Santacana M; Pané Foix M; Alonso MH; Navarro-Martin A; Comas Antón S; Guedea F Brachytherapy; 2020; 19(1):51-59. PubMed ID: 31690516 [TBL] [Abstract][Full Text] [Related]
13. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045 [TBL] [Abstract][Full Text] [Related]
14. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation. Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K; Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer. D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266 [TBL] [Abstract][Full Text] [Related]
17. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928 [TBL] [Abstract][Full Text] [Related]
19. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836 [TBL] [Abstract][Full Text] [Related]
20. Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial. Mitsuhashi A; Uno T; Usui H; Nishikimi K; Yamamoto N; Watanabe M; Tate S; Hirashiki K; Kato K; Yamazawa K; Shozu M Int J Gynecol Cancer; 2013 Oct; 23(8):1453-8. PubMed ID: 23266648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]